San Diego, Jan. 26, 2012 (Shareholders Foundation) -- The announcement by Amgen that it intends to will acquire Micromet for $11 per share prompted an investigation for investors in Micromet Inc. (NASDAQ:MITI) shares concerning whether the offer to acquire Micromet and the buyout process are unfair to investors in NASDAQ:MITI shares.

The investigations by law firms concern whether Micromet Inc, certain officers and directors, and/or others breached their fiduciary duties to Micromet (NASDAQ: MITI) investors in connection with the proposed acquisition.

On Jan. 26, 2012, Amgen (NASDAQ:AMGN) and Micromet, Inc. (NASDAQ:MITI) announced that the companies have entered into a merger agreement under which Amgen will acquire Micromet for $11 per share in cash or a transaction, which values Micromet at approximately $1.16 billion.

Following the takeover announcement shares of Micromet Inc. (MITI) jumped from $.827 on Wednesday to $10.94 on Thursday.

However, at least on analyst has set the high target price for NASDAQ:MITI shares at $12 per share, thus above the current offer.

However, the investigation for NASDAQ:MITI investors concerns whether the Micromet Board of Directors undertook an adequate sales process and in particular breached their fiduciary duties to Micromet Inc. (NASDAQ:MITI) shareholders by failing to adequately shop the Company before entering into this transaction. The investigation also focuses on whether offer by Amgen undervalues NASDAQ:MITI shares.

A potential securities class action lawsuit would seek to maximize the amount of money and information Micromet (MITI) shareholders would receive in a buyout, so the law firm.